Risperidone is expensive but, apparently, nottooexpensive. Recent Canadian guidelines suggest a cut-off point for how much spending can be justified per quality-adjusted life-year (QALY) gained when comparing old treatments with new. And a recent cost-utility study conducted by Janssen researchers has determined that risperidone comes close enough to this cut-off point to be recommended as treatment for schizophrenia. The results of this study were discussed at the 20th Annual Canadian Society of Hospital Pharmacists (Western Branches) [Banff, Alberta, Canada; March 1994].